A Review of Cannabis and Interactions With Anticoagulant and Antiplatelet Agents

@article{Greger2019ARO,
  title={A Review of Cannabis and Interactions With Anticoagulant and Antiplatelet Agents},
  author={J. Greger and Vernice Bates and Laszlo L. Mechtler and Francis M. Gengo},
  journal={The Journal of Clinical Pharmacology},
  year={2019},
  volume={60}
}
Legalization of medical cannabis has occurred in 33 states and the District of Columbia, and recreational use has increased exponentially since 2013. As a result, it is important to understand how cannabis interacts with other drugs and has potential risks for patients on concomitant medications. Components of medical cannabis can inhibit or compete for several cytochrome P450 (CYP) hepatic isoenzymes, UDP‐glucuronosyltransferases, and P‐glycoprotein. These enzymes and transporters are involved… Expand
Cannabis Use in Older Adults: A Perspective
TLDR
Special considerations pertinent to older adults are reviewed, specifically, the impact of cannabis on cognition and on falls and injuries, its drug interactions, and its potential medicinal applications for treating the behavioral and psychological symptoms of dementia. Expand
Cannabis Drug Interactions
TLDR
This chapter will provide an overview of the routes of administration as well as highlight potential drug interactions that cannabis products may have with particular classes of pharmaceuticals. Expand
Pharmacokinetic considerations about antiseizure medications in the elderly
TLDR
Overall, a reduction in loading and maintenance doses of almost all ASMs should be considered to avoid adverse events (AEs) as well as a slow titration, following the rule ‘start low and go slow’. Expand
"Is medical cannabis safe for my patients?" A practical review of cannabis safety considerations.
TLDR
A structured assessment and monitoring strategy that can be used by clinicians recomending cannabis (CRC) to guide patients through each step of their cannabis journey is proposed to ensure that medical cannabis utilization is associated with the lowest possible risk to the patient. Expand
A critical narrative review of medical cannabis in pediatrics beyond epilepsy, part I: background
In the past few decades, the use of marijuana, now commonly referred to as cannabis in the scientific community, has expanded globally to a myriad of medical conditions beyond epilepsy in pediatrics.Expand
Cannabidiol Products: Review of the Regulatory and Clinical Considerations
TLDR
A summary of the scientific evidence on CBD oil is provided so that a nurse practitioner can guide patients to the safest and most beneficial products within today’s regulatory environment. Expand
In vitro inhibitory effect of obtusofolin on the activity of CYP3A4, 2C9, and 2E1
TLDR
The in vitro inhibitory effect of obtusofolin is found to significantly inhibited the activity of CYP3A4, 2C9, and 2E1, implying the potential drug-drug interaction between obtUSofolin and corresponding substrates, which needs further in vivo validations. Expand
Translational hurdles with cannabis medicines
TLDR
The utility, limitations and impact of RWE in the translation of cannabis medicines research into clinical practice using the established literature are explored. Expand
Adverse events of recreational cannabis use reported to the French addictovigilance network (2012–2017)
TLDR
This study showed a multitude of AEs related to recreational cannabis use, including unexpected AEs and deaths, which highlights the problem of dependence and the emergence of cannabinoid hyperemesis syndrome. Expand
...
1
2
...

References

SHOWING 1-10 OF 51 REFERENCES
Interaction between warfarin and cannabis
TLDR
A case report of a 27-year-old man treated with warfarin due to mechanical heart valve replacement who presented with elevated international normalized ratio (INR) value ( INR = 4.6) following recreational cannabis use is described. Expand
The pharmacokinetics and the pharmacodynamics of cannabinoids.
TLDR
The limited availability of applicable pharmacokinetic and pharmacodynamic information highlights the need to initiate prescribing cannabis medicines using a 'start low and go slow' approach, carefully observing the patient for desired and adverse effects. Expand
Medicinal Cannabis—Potential Drug Interactions
TLDR
In general, cannabinoids are usually well tolerated, but bidirectional effects may be expected with concomitant administered agents via affected membrane transporters and metabolizing enzymes, especially for the elderly and people with chronic diseases or kidney and liver conditions. Expand
Probable Interaction Between Warfarin and Inhaled and Oral Administration of Cannabis
TLDR
There are no previous reports of interactions between edible cannabis and warfarin, with very few case reports describing the interaction with other forms of cannabis, but close monitoring of INR in patients with concomitant cannabis is recommended for proper warfar in management. Expand
Evaluating the Effect of Six Proton Pump Inhibitors on the Antiplatelet Effects of Clopidogrel.
TLDR
These data add data to a growing body of evidence indicating that the addition of a PPI may have a weak effect on clopidogrel's antiplatelet properties, and may only be relevant in specific clinical circumstances. Expand
The Potential for Pharmacokinetic Interactions Between Cannabis Products and Conventional Medications.
TLDR
This review aims to identify drug-metabolizing enzymes and drug transporters that are affected by concurrent cannabis use and, conversely, those co-prescribed medications that may alter the exposure to one or more cannabinoids. Expand
New Direct Oral Anticoagulants (DOAC) and Their Use Today
TLDR
The properties of oral administration, simple dosing without monitoring, a short half-life allowing for the possibility of uncomplicated switching or bridging, and proven safety overwhelm the disadvantages, making them an attractive option for short- or long-term anticoagulation. Expand
Novel antiplatelet agents in acute coronary syndrome
TLDR
The novel oral P2Y purinoceptor 12 (P2Y12)-receptor inhibitors prasugrel and ticagrelor were approved by the FDA for clinical use in 2009 and 2011 and have a faster-acting, more-potent, and more-predictable antiplatelet effect than clopidogrel. Expand
Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives
TLDR
The identification of factors contributing to the variation in clopidogrel response is needed to improve platelet inhibition and to reduce risk for cardiovascular events. Expand
A marijuana-drug interaction primer: Precipitants, pharmacology, and pharmacokinetics.
TLDR
This review articulates current issues surrounding marijuana terminology, taxonomy, and dosing; summarizes cannabinoid pharmacology and pharmacokinetics; and assesses the drug interaction risks associated with co-consuming marijuana with conventional medications. Expand
...
1
2
3
4
5
...